 CAMBRIDGE, Mass., Nov. 16, 2021 GLOBE NEWSWIRE -- Voyager Therapeutics, Inc. Nasdaq: VYGR, a gene therapy company developing life-changing treatments and next-generation adeno-associated virus AAV platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology SNO Annual Meeting on Nov. 19, 2021. 